Price Alert

Nektar Therapeutics (NKTR)

NASDAQ: NKTR · Real-Time Price · USD

27.24

0.55 (2.06%)

At close: Aug 15, 2025, 2:34 PM

2.06% (1D)

Bid	27.2
Market Cap	518.07M
Revenue (ttm)	87.25M
Net Income (ttm)	-133.04M
EPS (ttm)	-8.64
PE Ratio (ttm)	-3.15
Forward PE	-1.87
Analyst	Strong Buy

Ask	27.28
Volume	945,019
Avg. Volume (20D)	1,907,750
Open	26.80
Previous Close	26.69
Day's Range	26.34 - 28.22
52-Week Range	6.45 - 37.38
Beta	0.96

About NKTR

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NKTR

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NKTR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Nektar Therapeutics has released their quartely earnings on Aug 7, 2025:

Revenue of $11.18M exceeds estimates by $1.21M, with -52.42% YoY decline.

EPS of -2.95 exceeds estimates by 0.17, with 21.33% YoY growth.

Next Earnings Release

Nektar Therapeutics is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+156.29%

Nektar Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

1 month ago

+12.1%

Nektar Therapeutics shares are trading higher after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin on June 24, 2025.

News

1 week ago · seekingalpha.com

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript

Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief R...

1 week ago · fool.com

Why Nektar Therapeutics Stock Popped 6% on Friday

Biotech Nektar Therapeutics (NKTR 6.02%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, ...

6 days ago · zacks.com

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

6 days ago · fool.com

Nektar (NKTR) Q2 Revenue Falls 52%

1 week ago · zacks.com

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar Therapeutics (NKTR) came out with a quarterly loss of $2.95 per share versus the Zacks Consensus Estimate of a loss of $3.13. This compares to a loss of $3.75 per share a year ago.

3 weeks ago · marketbeat.com

3 Bullish Biotech Stocks With Explosive Growth Trends

Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo...

1 month ago · fool.com

Why Nektar Therapeutics Stock Dived by 3% Today

Nektar Therapeutics (NKTR -2.98%) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out...

1 month ago · marketbeat.com

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a...

1 month ago · marketbeat.com

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary an...

1 month ago · seekingalpha.com

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Load More News